Original Article

You have full text access to this OnlineOpen article

Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women

  1. Ana María Pino1,
  2. Susana Ríos1,
  3. Pablo Astudillo1,
  4. Mireya Fernández1,
  5. Paula Figueroa1,
  6. Germán Seitz2,
  7. J Pablo Rodríguez1,*

Article first published online: 18 MAR 2010

DOI: 10.1359/jbmr.090802

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 3, pages 492–498, March 2010

Additional Information

How to Cite

Pino, A. M., Ríos, S., Astudillo, P., Fernández, M., Figueroa, P., Seitz, G. and Rodríguez, J. P. (2010), Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res, 25: 492–498. doi: 10.1359/jbmr.090802

Author Information

  1. 1

    Laboratorio de Biología Celular, Instituto de Nutrición y Tecnología de los Alimentos (INTA), Universidad de Chile, Santiago, Chile

  2. 2

    Hospital Sótero del Río, Santiago, Chile

*Laboratorio de Biología Celular, INTA, Universidad de Chile, Macul 5540, Macul, Casilla 138-11, Santiago, Chile.

Publication History

  1. Issue published online: 18 MAR 2010
  2. Article first published online: 18 MAR 2010
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 30 JUL 2009
  5. Manuscript Revised: 22 JUN 2009
  6. Manuscript Received: 22 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (107K)

References

  • 1
    Zipori D. The stem state: mesenchymal plasticity as a paradigm. Curr Stem Cell Res Ther. 2006; 1: 95–102.
  • 2
    Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. Exp Biol Med. 2001; 226: 507–520.
  • 3
    Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006; 119: 3S–11S.
  • 4
    Wiig H, Berggreen E, Borge BA, Iversen PO. Demonstration of altered signaling responses in bone marrow extracellular fluid during increased hematopoiesis in rats using a centrifugation method. Am J Physiol Heart Circ Physiol. 2004; 286: H2028–H2034.
  • 5
    Iversen PO, Wiig H. tumor necrosis factor α and adiponectin in bone marrow interstitial fluid from patients with acute myeloid leukemia inhibit normal hematopoiesis. Clin Cancer Res. 2005; 11: 6793–6799.
  • 6
    Lee WY, Kang MI, Oh ES, et al. The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporos Int. 2002; 13: 62–68.
  • 7
    Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab. 1994; 79: 707–611.
  • 8
    Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol. 2004; 4: 290–294.
  • 9
    Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Prac Rheumatol. 2006; 2: 35–43.
  • 10
    Rodríguez JP, Astudillo P, Ríos S, Pino AM. Involvement of adipogenic potential of human bone marrow mesenchymal stem cells (MSCs) in osteoporosis. Stem Cell Res Ther. 2008; 3: 208–218.
  • 11
    Pittenger MF, Mackay AM, Beck SC, et al. Multineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143–147.
  • 12
    Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue: a quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res. 1971; 80: 147–154.
  • 13
    Ogawa S, Urano T, Hosoi T, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARγ expression in osteoblasts. Biochem Biophys Res Commun. 1999; 260: 122–126.
  • 14
    Bodine PV, Zhao W, Kharode YP, et al. The Wnt antagonist secreted frizzled related protein 1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol. 2004; 18: 1222–1237.
  • 15
    Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005; 102: 3324–3329.
  • 16
    Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev. 2006; 27: 449–467.
  • 17
    Yokota T, Meka CS, Medina KL, et al. Paracrine regulation of fat cell formation in bone marrow cultures via adiponectin and prostaglandins. J Clin Invest. 2002; 109: 1303–1310.
  • 18
    Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab. 2007; 92: 1517–1523.
  • 19
    Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of adiponectin. Med Mol Morphol. 2007; 40: 55–67.
  • 20
    Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002; 17: 1563–1569.
    Direct Link:
  • 21
    Laharrague P, Truel N, Fontanilles AM, Corberand JX, Penicaud L, Casteilla L. Regulation by cytokines of leptin expression in human bone marrow adipocytes. Horm Metab Res. 2000; 32: 381–385.
  • 22
    Lammert A, Kiess W, Bottner A, Glasow A, Kratzsch J. Soluble leptin receptor represents the main leptin binding activity in human blood. Biochem Biophys Res Commun. 2001; 283: 982–988.
  • 23
    Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation: studies in lean and obese subjects and during short-term fasting. J Clin Invest. 1996; 98: 1277–1282.
  • 24
    Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986; 319: 516–518.
  • 25
    Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990; 145: 3297–3303.
  • 26
    Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007; 65: S147–151.
    Direct Link:
  • 27
    Giuliani N, Sansoni P, Girasole G, et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes. Exp Gerontol. 2001; 36: 547–57.
  • 28
    Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008; 29: 155–192.
  • 29
    Mezquita-Raya P, de la Higuera M, Fernández García D, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int. 2005; 16: 1368–1374.
  • 30
    Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004; 291: 1108–1113.
  • 31
    Rodríguez JP, Garat S, Gajardo H, Pino AM, Seitz G. Abnormal osteogenesis in osteoporotic patients is reflected by altered mesenchymal stem cell dynamics. J Cell Biochem. 1999; 75: 414–423.
    Direct Link:
  • 32
    Raisz LG. The osteoporosis revolution. Ann Intern Med. 1997; 126: 458–462.
  • 33
    Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005; 16: 417–423.
  • 34
    Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R. Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008; 42: 623–630.
  • 35
    Tsuda E, Goto M, Mochizuki SI, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997; 234: 137–142.
  • 36
    Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95: 3597–3602.
  • 37
    Hess R, Pino AM, Ríos S, Fernández M, Rodríguez JP. High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cell Biochem. 2005; 94: 50–57.
    Direct Link:
  • 38
    Odabaşi E, Ozata M, Turan M, et al. Plasma leptin concentrations in postmenopausal women with osteoporosis. Eur J Endocrinol. 2000; 142: 170–173.
  • 39
    Shaarawy M, Abassi AF, Hassan H, Salem ME. Relationship between serum leptin concentrations and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis. Fertil Steril. 2003; 79: 919–924.
  • 40
    Weiss LA, Barrett-Connor E, von Mühlen D, Clark P. Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo Study. J Bone Miner Res. 2006; 21: 758–764.
    Direct Link:
  • 41
    Yano K, Tsuda N, Kobayashi F, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res. 1999; 14: 518–527.
    Direct Link:
  • 42
    Riggs BL, Khosla S, Atkinson EJ, Dunstan CR, Melton LJ III. Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporos Int. 2003; 14: 728–733.
  • 43
    Abrahamsen B, Bopnnevie-Nielsen V, Nils Ebbesen E, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study-hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res. 2000; 15: 1545–1554.
    Direct Link:
  • 44
    Nakchbandi I, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2002; 87: 4946–4951.
  • 45
    Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257: 79–83.
  • 46
    Hotta K, Funahashi T, Arita Y, et al. Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000; 20: 1595–1599.
  • 47
    Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways. Aging Cell. 2004; 3: 379–389.
    Direct Link:
  • 48
    Zayzafon M, Gathings WE, McDonald JM. Modeled microgravity inhibits osteogenic differentiation of human mesenchymal stem cells and increases adipogenesis. Endocrinology. 2004; 145: 2421–2432.
  • 49
    Astudillo P, Ríos S, Pastenes L, Pino AM, Rodríguez JP. Increased adipogenesis of osteoporotic human-msenchymal stem cells (MSCs) characterizes by impaired leptin action. J Cell Biochem. 2008; 103: 1054–1065.
    Direct Link:
  • 50
    Hozumi A, Osaki M, Goto H, Sakamoto K, Inokuchi S, Shindo H. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation. Biochem Biophys Res Commun. 2009; 382: 780–784.
  • 51
    Holloway WR, Collier FM, Aitken CJ, et al. Leptin inhibits osteoclast generation. J Bone Miner Res. 2002; 17: 200–209.
    Direct Link:
  • 52
    Martin A, de Vittoris R, David V, et al. Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology. 2005; 146: 3652–3659.
  • 53
    Unger RH. Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 2003; 14: 398–403.
  • 54
    Uotani S, Bjorbaek C, Tornoe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor down regulation. Diabetes. 1999; 48: 279–286.
  • 55
    Wang ZW, Zhou YT, Kakuma T, et al. Comparing the hypothalamic and extrahypothalamic actions of endogenous hyperleptinemia. Proc Natl Acad Sci USA. 1999; 96: 10373–10378.
  • 56
    Martin RL, Perez E, He YJ, Dawson R Jr, Millard WJ. Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein downregulation. Metabolism. 2000; 49: 1479–1484.
  • 57
    Sandhofer A, Laimer M, Ebenbichler CF, Kaser S, Paulweber B, Patsch JR. Soluble leptin receptor and soluble receptor-bound fraction of leptin in the metabolic syndrome. Obes Res. 2003; 11: 760–768.
  • 58
    Chan JL, Bluher S, Yiannakouris N, Suchard MA, Kratzsch J, Mantzoros CS. Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans. Diabetes. 2002; 51: 2105–2112.
  • 59
    Jiang L-S, Zhang Z-M, Jiang S-D, Chen W-H, Dai L-Y. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis. J Bone Miner Res. 2008; 23: 475–483.
    Direct Link:
View Full Article (HTML) Get PDF (107K)